Loading company
Pelthos Therapeutics Inc.
PTHS · NYSE · ·
$21.29-2.2%Sep 29 close
- 1M
- -13.9%
- 6M
- +1.4%
- 1Y
- -24.0%
PTHS · NYSE · ·
$21.29-2.2%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $15.6M | $0.00 | — |
| Profit | -$23.4M | -$3.4M | -578.95% |
| Profit per share | -$6.62 | -$0.06 | -11,936.36% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Pelthos Therapeutics Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. Zelsuvmi ® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes Xepi ® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and Xeglyze ® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com . Follow Pelthos on LinkedIn and X .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Pelthos Therapeutics Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.